{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:34:42Z","timestamp":1790130882350,"version":"4.0.1"},"reference-count":134,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jhep.2021.01.024","type":"journal-article","created":{"date-parts":[[2021,5,23]],"date-time":"2021-05-23T18:59:18Z","timestamp":1621796358000},"page":"S118-S134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"S1","title":["The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1439-056X","authenticated-orcid":false,"given":"Paolo","family":"Caraceni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3421-937X","authenticated-orcid":false,"given":"Juan G.","family":"Abraldes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Gin\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil N.","family":"Newsome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv K.","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2021.01.024_bib1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jhep.2017.10.020","article-title":"Clinical states of cirrhosis and competing risks","volume":"68","author":"D\u2019Amico","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41575-018-0045-2","article-title":"Novel perspectives in the management of decompensated cirrhosis","volume":"15","author":"Bernardi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.024_bib3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jhep.2020.08.009","article-title":"Endpoints and design of clinical trials in patients with decompensated cirrhosis: position paper of the LIVERHOPE consortium","volume":"74","author":"Sola","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2021.01.024_bib4","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/hep.30314","article-title":"Prioritization of therapeutic targets and trial design in cirrhotic portal hypertension","volume":"69","author":"Abraldes","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.024_bib5","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/S0140-6736(18)30840-7","article-title":"Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial","volume":"391","author":"Caraceni","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2021.01.024_bib6","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jhep.2018.08.006","article-title":"Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation.\u00a0A\u00a0randomized placebo-controlled trial","volume":"69","author":"Sol\u00e0","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(20)30751-0","article-title":"ATTIRE: albumin to prevent infection in chronic liver failure: an interventional randomised controlled trial","volume":"73","author":"China","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib8","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1053\/j.gastro.2018.08.026","article-title":"Effects of long-term norfloxacin therapy in patients with advanced cirrhosis","volume":"155","author":"Moreau","year":"2018","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jhep.2021.01.024_bib9","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2020.06.013","article-title":"The PREDICT study uncovers three clinical courses in acutely decompensated cirrhosis with distinct pathophysiology","volume":"73","author":"Trebicka","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib10","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1053\/j.gastro.2013.02.042","article-title":"Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis","volume":"144","author":"Moreau","year":"2013","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jhep.2021.01.024_bib11","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.jhep.2021.01.024_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41575-020-0293-9","article-title":"Head-to-head trials in inflammatory bowel disease: past, present and future","volume":"17","author":"Pouillon","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib13","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jhep.2015.07.004","article-title":"Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis","volume":"63","author":"Bernardi","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib14","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jhep.2020.11.048","article-title":"The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis","volume":"74","author":"Arroyo","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.024_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jhep.2021.01.024_bib16","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.024_bib17","doi-asserted-by":"crossref","first-page":"100063","DOI":"10.1016\/j.jhepr.2019.12.001","article-title":"Beta-blockers in cirrhosis: evidence-based indications and limitations","volume":"2","author":"Rodrigues","year":"2019","journal-title":"JHEP Rep"},{"issue":"5","key":"10.1016\/j.jhep.2021.01.024_bib18","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2018.06.017","article-title":"Exercise in cirrhosis: translating evidence and experience to practice","volume":"69","author":"Tandon","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.024_bib19","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jhep.2018.06.024","article-title":"EASL Clinical Practice Guidelines on nutrition in chronic liver disease","volume":"70","author":"European Association for the Study of the Liver","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib20","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/hep.29338","article-title":"Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: prediction and impact on long-term survival","volume":"66","author":"Altamirano","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.024_bib21","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jhep.2019.12.023","article-title":"Long-term outcomes in patients with decompensated alcohol-related liver disease, steatohepatitis and Maddrey's discriminant function < 32","volume":"72","author":"Degr\u00e9","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.024_bib22","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/hep.30358","article-title":"Diagnosis and treatment of alcohol use disorder in patients with end-stage alcoholic liver disease","volume":"70","author":"Caputo","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.024_bib23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/17474124.2020.1731303","article-title":"Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice","volume":"14","author":"El Sherif","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib24","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.28992","article-title":"Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study","volume":"65","author":"Berzigotti","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.024_bib25","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study","volume":"65","author":"Belli","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib26","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1053\/j.gastro.2018.03.022","article-title":"Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection","volume":"154","author":"El-Sherif","year":"2018","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jhep.2021.01.024_bib27","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jhep.2020.05.050","article-title":"Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension","volume":"73","author":"Lens","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib28","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jhep.2020.03.031","article-title":"DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: real-world experience from HCV-TARGET cohort","volume":"73","author":"Verna","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib29","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/TP.0000000000001708","article-title":"International Liver Transplantation Society consensus statement on hepatitis C management in liver transplant candidates","volume":"101","author":"Terrault","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2021.01.024_bib30","first-page":"30263","article-title":"Disease progression in patients with hepatitis C virus infection treated with Direct-Acting Antiviral agents","volume":"28","author":"Mendizabal","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib31","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2012.02.033","article-title":"Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy","volume":"57","author":"Peng","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib32","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"EASL clinical practice guidelines: liver transplantation","volume":"64","author":"European Association for the Study of the Liver","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2021.01.024_bib33","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12016-016-8583-2","article-title":"The management of autoimmune hepatitis patients with decompensated cirrhosis: real-world experience and a comprehensive review","volume":"52","author":"Wang","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jhep.2021.01.024_bib34","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(20)31607-X","article-title":"Primary biliary cholangitis","volume":"396","author":"Lleo","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jhep.2021.01.024_bib35","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00535-020-01681-z","article-title":"Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities","volume":"55","author":"Vesterhus","year":"2020","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jhep.2021.01.024_bib36","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1432-2277.2009.00863.x","article-title":"Outcome of liver transplantation in hereditary hemochromatosis","volume":"22","author":"Dar","year":"2009","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2021.01.024_bib37","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1053\/jhep.2003.50038","article-title":"Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement","volume":"37","author":"Albillos","year":"2003","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2021.01.024_bib38","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/hep.1840120416","article-title":"Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial","volume":"12","author":"Gin\u00e9s","year":"1990","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.024_bib39","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1053\/j.gastro.2007.06.065","article-title":"Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis","volume":"133","author":"Fern\u00e1ndez","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.01.024_bib40","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/liv.14109","article-title":"Comparative efficacy of long-term antibiotic treatments in the primary prophylaxis of spontaneous bacterial peritonitis","volume":"39","author":"Facciorusso","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.01.024_bib41","article-title":"Efficacy of norfloxacin prophylaxis to prevent spontaneous bacterial peritonitis: a systematic review and meta-analysis","volume":"8","author":"M\u00fccke","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.jhep.2021.01.024_bib42","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","author":"Angeli","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib43","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jhep.2014.01.024","article-title":"Bacterial infections in cirrhosis: a position statement on the EASL special conference 2013","volume":"60","author":"Jalan","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib44","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1053\/j.gastro.2018.12.005","article-title":"Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide","volume":"156","author":"Piano","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.01.024_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31708","article-title":"The use of rifaximin in patients with cirrhosis","author":"Caraceni","year":"2021","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2021.01.024_bib46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/apt.13435","article-title":"Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis","volume":"43","author":"Bajaj","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2021.01.024_bib47","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/MEG.0000000000000743","article-title":"Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival","volume":"28","author":"Hanafy","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib48","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3748\/wjg.v26.i2.199","article-title":"Rifaximin improves survival in cirrhotic patients with refractory ascites: a real-world study","volume":"26","author":"Lv","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.01.024_bib49","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/apt.14275","article-title":"Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patient experiencing hepatic encephalopathy","volume":"46","author":"Kang","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2021.01.024_bib50","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818800307","article-title":"Rifaximin has the potential to prevent complications of cirrhosis","volume":"11","author":"Flamm","year":"2018","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.jhep.2021.01.024_bib51","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/apt.15326","article-title":"Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list","volume":"50","author":"Salehi","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2021.01.024_bib52","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/jgh.12070","article-title":"Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis","volume":"28","author":"Vlachogiannakos","year":"2013","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib53","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1097\/MEG.0000000000000967","article-title":"Long-term rifaximin therapy as a primary prevention of\u00a0hepatorenal syndrome","volume":"29","author":"Ibrahim","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib54","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1007\/s10620-016-4313-0","article-title":"Rifaximin decreases the incidence and severity of acute kidney injury and hepatorenal syndrome in cirrhosis","volume":"61","author":"Dong","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2021.01.024_bib55","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12072-015-9688-z","article-title":"Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study","volume":"10","author":"Assem","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2021.01.024_bib56","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/MEG.0000000000000724","article-title":"Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis","volume":"28","author":"Elfert","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib57","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/MEG.0000000000000940","article-title":"Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis","volume":"29","author":"Kamal","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib58","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/apt.14361","article-title":"Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis","volume":"46","author":"Goel","year":"2017","journal-title":"Am Pharmacol Ther"},{"key":"10.1016\/j.jhep.2021.01.024_bib59","article-title":"Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis","volume":"1","author":"Komolafe","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhep.2021.01.024_bib60","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jhep.2018.07.019","article-title":"Statins: old drugs as new therapy for liver disease?","volume":"70","author":"Pose","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib61","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1136\/gutjnl-2019-318237","article-title":"Cirrhosis as new indication for statins","volume":"69","author":"Bosch","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.01.024_bib62","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","article-title":"Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis","volume":"126","author":"Zafra","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.01.024_bib63","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/SHK.0000000000000734","article-title":"Simvastatin attenuates liver Injury in rodents with biliary cirrhosis. Submitted to Hemorrhage\/Resuscitation","volume":"47","author":"Meireles","year":"2017","journal-title":"Shock"},{"key":"10.1016\/j.jhep.2021.01.024_bib64","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1053\/j.gastro.2018.07.022","article-title":"Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension","volume":"155","author":"Tripathi","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.01.024_bib65","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1136\/gutjnl-2014-308338","article-title":"KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins","volume":"64","author":"Marrone","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.01.024_bib66","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/hep.21673","article-title":"Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase","volume":"46","author":"Trebicka","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.024_bib67","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.01.024_bib68","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","article-title":"Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial","volume":"47","author":"Pollo-Flores","year":"2015","journal-title":"Dig Liv Dis"},{"key":"10.1016\/j.jhep.2021.01.024_bib69","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/MEG.0000000000001006","article-title":"Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study","volume":"30","author":"Bishnu","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib70","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1016\/j.jhep.2021.01.024_bib71","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1056\/NEJMra1914900","article-title":"Acute-on-Chronic liver failure","volume":"382","author":"Arroyo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.01.024_bib72","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2468-1253(19)30320-6","article-title":"Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double blind, placebo-controlled, phase 2 trial","volume":"5","author":"Pose","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib73","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/liv.13308","article-title":"Hepatotoxicity of statins and other lipid-lowering agents","volume":"37","author":"Bjornsson","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.01.024_bib74","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2468-1253(19)30320-6","article-title":"Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double blind, placebo-controlled, phase 2 trial","volume":"5","author":"Pose","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib75","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.26338","article-title":"Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications","author":"Garcia-Martinez","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.024_bib76","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/gutjnl-2019-318843","article-title":"Albumin in decompensated cirrhosis - new concepts and perspectives","volume":"69","author":"Bernardi","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.01.024_bib77","series-title":"Management of adult patients with ascites due to cirrhosis: Update","author":"Runyon","year":"2012"},{"key":"10.1016\/j.jhep.2021.01.024_bib78","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jhep.2012.06.013","article-title":"Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study","volume":"57","author":"Guevara","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib79","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jhep.2014.11.017","article-title":"Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial","volume":"62","author":"Th\u00e9venot","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib80","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.jhep.2013.07.020","article-title":"Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study","volume":"59","author":"Sim\u00f3n-Talero","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib81","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.cgh.2019.07.055","article-title":"Efficacy of albumin treatment for patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis","volume":"18","author":"Fern\u00e1ndez","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib82","article-title":"On-treatment serum albumin level as guide for long-term albumin treatment of patients with cirrhosis and uncomplicated ascites","author":"Caraceni","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib83","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.gastro.2019.03.021","article-title":"Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis","volume":"157","author":"Fern\u00e1ndez","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.01.024_bib84","doi-asserted-by":"crossref","first-page":"M18","DOI":"10.1093\/geronj\/43.1.M18","article-title":"The effect of age on serum albumin in healthy males: report from the Normative Aging Study","volume":"43","author":"Campion","year":"1988","journal-title":"J\u00a0Gerontol"},{"issue":"4","key":"10.1016\/j.jhep.2021.01.024_bib85","first-page":"100122","article-title":"Where does TIPS fit in the management of patients with cirrhosis?","volume":"2","author":"Garcia-Pagan","year":"2020","journal-title":"J\u00a0Hep Rep"},{"key":"10.1016\/j.jhep.2021.01.024_bib86","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/hep.20386","article-title":"Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding","volume":"40","author":"Monescillo","year":"2004","journal-title":"Hepatology"},{"issue":"25","key":"10.1016\/j.jhep.2021.01.024_bib87","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1056\/NEJMoa0910102","article-title":"Early use of TIPS in patients with cirrhosis and variceal bleeding","volume":"362","author":"Garcia-Pagan","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.jhep.2021.01.024_bib88","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S2468-1253(19)30090-1","article-title":"Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial","volume":"4","author":"Lv","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2021.01.024_bib89","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jhep.2020.04.024","article-title":"Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS","volume":"73","author":"Trebicka","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.024_bib90","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jhep.2020.06.010","article-title":"Determinants of mortality in patients with cirrhosis and uncontrolled variceal bleeding","volume":"74","author":"Kumar","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2021.01.024_bib91","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0168-8278(96)80065-1","article-title":"Transjugular intrahepatic portosystemic shunts: comparison with par- acentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists","volume":"25","author":"Lebrec","year":"1996","journal-title":"J\u00a0Hepatol"},{"issue":"23","key":"10.1016\/j.jhep.2021.01.024_bib92","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1056\/NEJM200006083422303","article-title":"A\u00a0comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites","volume":"342","author":"Rossle","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jhep.2021.01.024_bib93","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1053\/gast.2002.37073","article-title":"Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis","volume":"123","author":"Gines","year":"2002","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jhep.2021.01.024_bib94","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1053\/gast.2003.50088","article-title":"The North American study for the treatment of refractory ascites","volume":"124","author":"Sanyal","year":"2003","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jhep.2021.01.024_bib95","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/hep.20364","article-title":"Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites","volume":"40","author":"Salerno","year":"2004","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.024_bib96","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00535-010-0282-9","article-title":"Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial","volume":"46","author":"Narahara","year":"2011","journal-title":"J\u00a0Gastroenterol"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.024_bib97","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/j.gastro.2016.09.016","article-title":"Transjugular intrahepatic portosystemic shunts with covered stents in- crease transplant-free survival of patients with cirrhosis and recurrent ascites","volume":"152","author":"Bureau","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.01.024_bib98","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"De Franchis","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib99","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases","volume":"65","author":"Garcia-Tsao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.024_bib100","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jhep.2012.12.011","article-title":"Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis","volume":"58","author":"Reiberger","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.024_bib101","doi-asserted-by":"crossref","first-page":"100063","DOI":"10.1016\/j.jhepr.2019.12.001","article-title":"Beta-blockers in cirrhosis: evidence-based indications and limitations","volume":"2","author":"Rodrigues","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2021.01.024_bib102","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s12072-019-09986-9","article-title":"Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial","volume":"13","author":"Kumar","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2021.01.024_bib103","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/hep.22317","article-title":"Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial","volume":"48","author":"Spahr","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.024_bib104","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1053\/j.gastro.2011.11.027","article-title":"Gran- ulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure","volume":"142","author":"Garg","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.01.024_bib105","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/ajg.2014.154","article-title":"Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study","volume":"109","author":"Singh","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.01.024_bib106","article-title":"Effect of granulocyte colony-stimulating factor (G-CSF) on mortality and complications viz. sepsis, encephalopathy, hepatorenal syndrome, and gastrointestinal bleed in severe alcoholic hepatitis: a randomized controlled study","volume":"5","author":"Sharma","year":"2017","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.jhep.2021.01.024_bib107","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.cgh.2018.01.040","article-title":"Efficacy of granulocyte colony-stimulating factor and N-acetylcysteine therapies in patients with severe alcoholic hepatitis","volume":"16","author":"Singh","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib108","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/hep.30516","article-title":"Efficacy of granulocyte colony-stimulating factor in the management of steroid- nonresponsive severe alcoholic hepatitis: a double-blind randomized controlled trial","volume":"70","author":"Shasthry","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jhep.2021.01.024_bib109","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jceh.2019.05.003","article-title":"Granulocyte colony-stimulating factor use in decompensated cirrhosis: lack of survival benefit","volume":"10","author":"Philips","year":"2020","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib110","article-title":"G-CST to treat ACLF (GRAFT TRIAL): interim analysis of the first randomised European multicentral trial","author":"Engelmann","year":"2019","journal-title":"AASLD"},{"key":"10.1016\/j.jhep.2021.01.024_bib111","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/MEG.0000000000000801","article-title":"Granulocyte colony-stimulating factor improves survival of patients with decompensated cirrhosis: a randomized-controlled trial","volume":"29","author":"Prajapati","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib112","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1053\/j.gastro.2015.02.054","article-title":"Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis","volume":"148","author":"Kedarisetty","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.01.024_bib113","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/hep.29763","article-title":"Outcomes after multiple courses of granulocyte colony-stimulating factor and growth hormone in decompensated cirrhosis: a randomized trial","volume":"68","author":"Verma","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.024_bib114","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S2468-1253(17)30326-6","article-title":"Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial","volume":"3","author":"Newsome","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib115","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cgh.2020.02.022","article-title":"Multiple cycles of granulocyte colony-stimulating factor increase survival times of patients with decompensated cirrhosis in a randomized trial","volume":"19","author":"De","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2021.01.024_bib116","doi-asserted-by":"crossref","first-page":"100139","DOI":"10.1016\/j.jhepr.2020.100139","article-title":"Granulocyte colony-stimulating factor for alcoholic hepatitis: a systematic review and meta-analysis of randomised controlled trials","volume":"2","author":"Marot","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2021.01.024_bib117","doi-asserted-by":"crossref","DOI":"10.1007\/s00134-019-05783-y","article-title":"Extracorporeal liver support in patients with liver failure: a systematic review and meta-analysis of randomized trials","author":"Alshamsi","year":"2020","journal-title":"Int Care Med"},{"issue":"2","key":"10.1016\/j.jhep.2021.01.024_bib118","article-title":"Update on extracorporeal liber support","volume":"26","author":"Katarey","year":"2020","journal-title":"Curr Opion Crit Care"},{"key":"10.1016\/j.jhep.2021.01.024_bib119","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1053\/j.gastro.2011.12.056","article-title":"Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure","volume":"142","author":"Kribben","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.01.024_bib120","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/hep.26185","article-title":"Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial","volume":"57","author":"Banares","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.01.024_bib121","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/lt.24986","article-title":"Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: a multinational, prospective, controlled, randomized trial","volume":"24","author":"Thompson","year":"2018","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2021.01.024_bib122","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/bph.13798","article-title":"Drug repurposing from the perspective of pharmaceutical companies","volume":"175","author":"Cha","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.jhep.2021.01.024_bib123","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib124","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1126\/science.282.5396.2085","article-title":"Defective LPS signaling in C3H\/HeJ and C57BL\/10ScCr mice: mutations in TLR4 gene","volume":"282","author":"Poltorak","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jhep.2021.01.024_bib125","doi-asserted-by":"crossref","first-page":"8314","DOI":"10.3748\/wjg.v21.i27.8314","article-title":"TLR4-HMGB1-, MyD88- and TRIF-dependent signaling in mouse intestinal ischemia\/reperfusion injury","volume":"21","author":"Wang","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.01.024_bib126","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1124\/mol.110.068064","article-title":"TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules","volume":"79","author":"Matsunaga","year":"2011","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.024_bib127","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jhep.2020.01.011","article-title":"Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure","volume":"73","author":"Engelmann","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.01.024_bib128","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nure.12082","article-title":"Intestinal alkaline phosphatase: novel functions and protective effects","volume":"72","author":"Lalles","year":"2014","journal-title":"Nutr Rev"},{"key":"10.1016\/j.jhep.2021.01.024_bib129","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41598-019-57284-z","article-title":"Recombinant alkaline phosphatase prevents acute on chronic liver failure","volume":"10","author":"Engelmann","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jhep.2021.01.024_bib130","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.3390\/metabo11010009","article-title":"Cholesterol metabolites 25-hydroxycholesterol and 25-hydroxycholesterol 3-sulfate are potent paired regulators: from discovery to clinical usage","volume":"11","author":"Wang","year":"2020","journal-title":"Metabolites"},{"key":"10.1016\/j.jhep.2021.01.024_bib131","article-title":"Cholesterol and oxysterol sulfates: pathophysiological roles and analytical challenges","author":"Sanchez","year":"2020","journal-title":"Br J Pharmacol"},{"issue":"S1","key":"10.1016\/j.jhep.2021.01.024_bib132","first-page":"834A","article-title":"Safety and efficacy of DUR-928: a potential new therapy for acute alcoholic hepatitis","volume":"70","author":"Hassanein","year":"2019","journal-title":"Hepatology"},{"issue":"S1","key":"10.1016\/j.jhep.2021.01.024_bib133","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1016\/S0168-8278(20)30869-2","article-title":"Pharmacokinetics of DUR-928 in alcoholic hepatitis patients - a phase 2a study","volume":"73","author":"Shah","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2021.01.024_bib134","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.3748\/wjg.v25.i15.1783","article-title":"Repurposing drugs to target non-alcoholic steatohepatitis","volume":"25","author":"Sookoian","year":"2019","journal-title":"World\u00a0J Gastroenterol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821000362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821000362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:41:40Z","timestamp":1759174900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821000362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":134,"alternative-id":["S0168827821000362"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.01.024","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}